157 related articles for article (PubMed ID: 17296594)
1. The V617F mutation of JAK2 is very uncommon in patients with thrombosis.
Remacha AF; Estivill C; Sarda MP; Mateo J; Souto JC; Canals C; Nomdedéu J; Fontcuberta J
Haematologica; 2007 Feb; 92(2):285-6. PubMed ID: 17296594
[TBL] [Abstract][Full Text] [Related]
2. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
3. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
4. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
5. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
6. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.
Finazzi G; Rambaldi A; Guerini V; Carobbo A; Barbui T
Haematologica; 2007 Jan; 92(1):135-6. PubMed ID: 17229651
[TBL] [Abstract][Full Text] [Related]
7. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
8. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia.
Gangemi S; Allegra A; Pace E; Alonci A; Ferraro M; Petrungaro A; Saitta S; Gerace D; Russo S; Penna G; Musolino C
Cell Immunol; 2012; 278(1-2):91-4. PubMed ID: 23121980
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
[TBL] [Abstract][Full Text] [Related]
11. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
[No Abstract] [Full Text] [Related]
12. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
[TBL] [Abstract][Full Text] [Related]
13. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
14. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.
Carobbio A; Finazzi G; Antonioli E; Guglielmelli P; Vannucchi AM; Dellacasa CM; Salmoiraghi S; Delaini F; Rambaldi A; Barbui T
Exp Hematol; 2009 Sep; 37(9):1016-21. PubMed ID: 19559071
[TBL] [Abstract][Full Text] [Related]
15. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.
Chim CS; Sim JP; Chan CC; Kho BC; Chan JC; Wong LG; Law M; Liang R; Kwong YL
Hematology; 2010 Aug; 15(4):187-92. PubMed ID: 20670476
[TBL] [Abstract][Full Text] [Related]
16. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
17. Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia.
Trifa AP; Bănescu C; Voina CM; Popa Ș; Török-Vistai T; Bojan AS; Dima D; Zdrenghea M; Fetica B; Vișan S; Tomuleasa C; Pârvu A; Urian L; Pop B; Popov VM; Andreescu M; Popp RA
Blood Cells Mol Dis; 2018 Nov; 73():45-46. PubMed ID: 30249383
[No Abstract] [Full Text] [Related]
18. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of risk factors for thromboembolism in patients with JAK2
Zhang YH; Teng GS; Ma JY; Hu X; Du CX; Wang Y; Hu NB; Li YQ; Shao ZH; Bai J
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3652-3657. PubMed ID: 38018064
[No Abstract] [Full Text] [Related]
20. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.
Dahabreh IJ; Zoi K; Giannouli S; Zoi C; Loukopoulos D; Voulgarelis M
Leuk Res; 2009 Jan; 33(1):67-73. PubMed ID: 18632151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
